Suppr超能文献

与神经管缺陷和胶质母细胞瘤相关的基因。

Genes related to neural tube defects and glioblastoma.

作者信息

Cao Rui, Liu Yurong, Wei Kaixin, Jin Ning, Liang Yuxiang, Ao Ruifang, Pan Weiwei, Wang Xiang, Wang Xiuwei, Zhang Li, Xie Jun

机构信息

Department of Biochemistry and Molecular Biology, Shanxi Key Laboratory of Birth Defect and Cell Regeneration, Key Laboratory of Coal Environmental Pathogenicity and Prevention (Ministry of Education, China, Shanxi Medical University, No. 56, Xinjian South Road, Yingze District, Taiyuan City, 030000, Shanxi Province, China.

Translational Medicine Research Centre, Shanxi Medical University, Taiyuan, 030000, China.

出版信息

Sci Rep. 2025 Jan 30;15(1):3777. doi: 10.1038/s41598-025-86891-2.

Abstract

There are many similarities between early embryonic development and tumorigenesis. The occurrence of neural tube defects (NTDs) and glioblastoma (GBM) are both related to the abnormal development of neuroectodermal cells. To obtain genes related to both NTDs and GBM, as well as small molecule drugs with potential clinical application value. We performed bioinformatics analysis on transcriptome sequencing data of retinoic acid (RA)-induced NTDs mice, human NTDs samples and GBM samples. RT-qPCR, Western blot, and immunohistochemistry were used to validate the expression of candidate genes. Our results indicated that two genes at mRNA and protein levels have been well verified in both NTDs mouse and GBM human samples, namely, Poli and Fgf1. Molecular docking and validating in vitro were performed for FGF1 against pazopanib by using Autodock and Biacore. Cytological experiments showed that pazopanib significantly inhibited the proliferation of GBM tumor cells and mouse neural cells, promoted apoptosis, and had no effect on GBM tumor cells migration. Overall, our results demonstrated that Fgf1 abnormally expressed at different developmental stages, it may be a potentially prenatal biomarker for NTDs and potential therapeutic target for GBM. Pazopanib may be a new drug for the treatment of GBM tumors.

摘要

早期胚胎发育与肿瘤发生之间存在许多相似之处。神经管缺陷(NTDs)和胶质母细胞瘤(GBM)的发生均与神经外胚层细胞的异常发育有关。为了获得与NTDs和GBM相关的基因,以及具有潜在临床应用价值的小分子药物。我们对维甲酸(RA)诱导的NTDs小鼠、人类NTDs样本和GBM样本的转录组测序数据进行了生物信息学分析。采用RT-qPCR、蛋白质免疫印迹和免疫组织化学法验证候选基因的表达。我们的结果表明,在NTDs小鼠和GBM人类样本中,两个基因在mRNA和蛋白质水平均得到了很好的验证,即Poli和Fgf1。利用Autodock和Biacore对FGF1与帕唑帕尼进行分子对接和体外验证。细胞学实验表明,帕唑帕尼显著抑制GBM肿瘤细胞和小鼠神经细胞的增殖,促进细胞凋亡,对GBM肿瘤细胞迁移无影响。总体而言,我们的结果表明,Fgf1在不同发育阶段异常表达,它可能是NTDs潜在的产前生物标志物和GBM的潜在治疗靶点。帕唑帕尼可能是一种治疗GBM肿瘤的新药。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f06f/11782569/d4ce90f561cc/41598_2025_86891_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验